Context: Preterm birth is associated with short stature, abdominal adiposity, insulin resistance, and hypertension, resembling effects of increased glucocorticoid bioactivity. Although antenatal glucocorticoid treatment does not substantially contribute to these associations, it is unknown whether genetic variants in the glucocorticoid receptor gene could modulate the effects of antenatal glucocorticoid treatment on the above phenotype.
T he long-term metabolic consequences of preterm birth include increased risks of short stature, abdominal adiposity, insulin resistance, and hypertension (1, 2) , resembling effects of increased glucocorticoid bioactivity. It has been suggested that glucocorticoid therapy to mothers with impending preterm delivery contributes to these risks. However, previous studies have yielded contradictory results, and consequently, there is no compelling evidence for metabolic side effects of maternal glucocorticoid treatment in preterm offspring (3) (4) (5) .
We speculate that the long-term metabolic consequences of maternal glucocorticoid treatment in preterm offspring are dependent on glucocorticoid receptor (GR) polymorphisms. The 363S variant of the N363S polymorphism has been associated with an increased sensitivity to glucocorticoids and obesity and cardiovascular disease (6) . The 23K variant of the R23K polymorphism has been associated with a decreased sensitivity to glucocorticoids and a favorable metabolic health (6) .
In this study, we tested whether the effects of antenatal glucocorticoid treatment on adult metabolic outcomes are dependent on the above GR polymorphisms in young adults born preterm. In comparison, effects of early postnatal glucocorticoid treatment on these outcomes were also investigated.
Subjects and Methods

Subjects
Subjects were drawn from the Project on Preterm and Smallfor-Gestational-Age Infants (POPS), which follows a large cohort comprising 94% of all live-born very preterm (Ͻ32 wk gestation) and/or very-low-birth-weight (Ͻ1500 g) infants born in The Netherlands in 1983 (7) . In that year, a single treatment course of betamethasone 12 mg administered twice with a 24-h interval was the only therapy used to accelerate fetal lung maturation in The Netherlands. In the early 1980s, fear for possible long-term deleterious effects on the unborn child restrained many obstetricians from administrating betamethasone to mothers with impending preterm delivery, whereas others prescribed this therapy routinely or frequently (8) . Preterm infants who could not be weaned from the ventilator were always given dexamethasone for a more prolonged period (e.g. 2 wk).
At age 19, all 676 alive subjects born under 32 wk gestation were approached by mail to participate in the POPS-19 study, of whom 422 consented to participate (62% response). Nonresponse in the POPS-19 study was associated with male gender, lower education, non-Dutch descent, and handicaps (9) . Only the nonsyndromic subjects were eligible for this specific study. Subjects with diabetes mellitus type 1 or on thyroid hormone or systemic corticosteroid, as well as non-Caucasian subjects and pregnant women were excluded. The data of 14 subjects who had attended nonfasted were not analyzed either for comparisons with laboratory parameters as outcomes. The approval of the medical ethical committees of all participating centers was obtained for the POPS-19 study.
Study protocol
Subjects who gave written informed consent were studied after an overnight fast between 0830 and 1000 h at one of the outpatient clinics of the 10 participating centers. Assessors were blinded with respect to the perinatal characteristics of the subjects.
After 30 min in supine position, blood pressure was measured three times consecutively with an automatic blood pressure device (Dinamap; Critikon, Norderstedt, Germany) at the nondominant arm. Venous blood was subsequently obtained. There- 
Laboratory analyses
Glucose and total cholesterol levels were measured in a fully automated computerized laboratory system with a Hitachi 747 chemistry analyzer (Hitachi, Tokyo, Japan). High-density lipoprotein and low-density lipoprotein levels were measured with a turbidimetric assay on a Hitachi 911. Insulin and C-peptide levels were measured with highly sensitive RIA (Linco, St. Charles, MO; detection levels of 0.1 mU/liter and 0.03 mmol/liter, respectively; interassay coefficients of variation of 4.7-12.2% and 3.2-9.3% at different levels, respectively). Homeostatic model assessment for insulin resistance index (HOMA-IR) was calculated (12) .
For both the R23K (rs6190) and N363S (rs6195) single-nucleotide polymorphisms, PCR were performed using 2.5 ng genomic DNA and standard reagents. Single-nucleotide polymorphisms were subsequently genotyped by mass spectrometry (homogeneous mass array system; Sequenom Inc., San Diego, CA), using standard conditions. Genotypes were analyzed by using Genotyper version 3.0 software (Sequenom).
Statistical analysis
Auxological data at birth and obtained on subsequent occasions were converted to SD score (SDS), to correct for (gestational) age and sex, using Swedish references for preterm infants (13) and Dutch references (10, 14, 15) , respectively. Variables with non-Gaussian distributions (insulin and HOMA-IR) were log 10 -transformed before statistical comparison. Modification by antenatal glucocorticoid treatment of the effect of genotype on outcomes was tested by first including the variables genotype (in which minor allele carrier ϭ 1 and noncarrier ϭ 0) and antenatal glucocorticoid treatment (in which yes ϭ 1 and no ϭ 0) in a linear regression analysis followed by the inclusion of their product. Analyses were repeated after inclusion of gender and the obstetric data listed in Table 1 in the regression model.
Results
We identified 24 subjects (9.1%) who were heterozygous for the 23K variant and 15 (5.7%) who were heterozygous for the 363S variant. Nobody was carrier of both variants. The corresponding allele frequencies of 4.6 and 2.9%, respectively, were reasonably well in range with the allele frequencies in the Dutch population (16) . Genotype distributions were in Hardy-Weinberg equilibrium.
Fifty-six subjects (21.3%) had been exposed antenatally to glucocorticoid treatment. Nineteen subjects (7.2%) had received postnatal glucocorticoid treatment, two of whom had also been exposed to glucocorticoids in utero. One of the subjects who had been exposed to glucocorticoids in both perinatal phases was carrier of the 363S variant.
Perinatal characteristics did not differ significantly between the GR genotypes, with the exception of an unequal distribution in the numbers who had been treated with glucocorticoids as neonates ( Table 1) . Among postnatally treated subjects, allele frequencies of the 23K and 363S variants were 0 and 10.5%, respectively. Carriage of 23K tended to associate with hypertension during pregnancy (P ϭ 0.05), being part of a multiple pregnancy (P ϭ 0.07), and premature rupture of membranes (P ϭ 0.07). Hyper- tension during pregnancy was inversely associated with antenatal glucocorticoid treatment (7.1% in exposed vs. 19 .8% in unexposed subjects; P ϭ 0.03). Table 2 shows the metabolic profile at 19 yr of age by GR genotype and antenatal glucocorticoid treatment. Waist circumference was 1.67 Ϯ 0.90 SDS in 363S carriers who had been treated antenatally with glucocorticoids (363S/GC ϩ ), which was much higher than that of the other groups (P for interaction ϭ 0.03). A similar association was found for the waist-to-hip ratio SDS (P ϭ 0.03). There was a tendency toward a higher C-peptide level in the 363S/GC ϩ group (P ϭ 0.08). Correction for antenatal variables or exclusion of postnatally treated subjects hardly changed the strength of these associations. No such associations were found with the R23K polymorphism. Absolute and relative fat mass were greater in 363S carriers who had received glucocorticoids as neonates (P ϭ 0.04 and P ϭ 0.05, respectively), which relations became stronger after exclusion of antenatally treated subjects (P ϭ 0.005 and P ϭ 0.01, respectively). The direction of association was similar for waist circumference SDS, but the test for interaction was not significant (P ϭ 0.17). Interaction between 363S carriage and early glucocorticoid exposure (antenatal and/or postnatal) on adult outcomes was observed for waist circumference SDS (P ϭ 0.01), waist-to-hip ratio SDS (P ϭ 0.05), absolute fat mass (P ϭ 0.003), and fat percentage (P ϭ 0.006).
Discussion
In this study in 19-yr-old survivors of very preterm birth, we found that antenatal glucocorticoid treatment was associated with abdominal adiposity in carriers of the 363S variant. However, also in the other groups, the waist circumference SDS was greater than the population reference mean, implying that 363S carriage ϫ early glucocorticoid exposure interaction could not wholly account for the metabolic perturbations in our cohort. Because in our sample only four subjects had the combination of 363S carriage and antenatal glucocorticoid treatment, we strongly recommend replication in larger preterm populations.
The 363S variant is associated with an increased sensitivity to glucocorticoids and obesity and cardiovascular disease (6) . However, this effect is limited, because a metaanalysis showed that carriers of the 363S variant had only a 0.18 (95% confidence interval ϭ 0.004 -0.35) kg/m 2 greater body mass index compared with noncarriers (17) .
Some limitations of our study should be discussed. First, it is unclear whether the relation between antenatal glucocorticoid treatment and reduced neonatal mortality (18) is dependent on the GR genotype and, thus, could introduce selection bias. Survivor effects cannot be excluded, considering the altered allele frequencies among postnatally treated subjects. Second, selection bias could also be introduced by the nonrandomized assignment of glucocorticoid therapy. Nineteen-year-old survivors who had been treated antenatally with glucocorticoids were less often born after a hypertensive pregnancy. A possible explanation for this association is that the involved obstetricians may have been less inclined to prescribe glucocorticoids to mothers with pregnancy-induced hypertension. However, other explanations for this relation cannot be excluded, such as selective survival among the unex- Values represent mean Ϯ SD. DBP, Diastolic blood pressure; GC ϩ , exposed to glucocorticoids antenatally; GC Ϫ , not exposed to glucocorticoids antenatally; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; WHR, waist-to-hip ratio. a Values represent crude P value/adjusted P value/P value after exclusion of 19 postnatally treated subjects.
b Log-transformed value.
posed group of those who were born after a hypertensive pregnancy. Furthermore, it has been argued that the side effects of a therapy can be studied with an observational study as reliably as with a randomized trial, provided that these cannot be predicted at the time of prescription (19) . Third, the relatively small number of subjects who had been treated with glucocorticoids antenatally and who carry the 363S variant raises the possibility of chance findings. Although a true independent replication would be helpful, to our knowledge, the few preterm cohorts that have been followed into adulthood have not been genotyped (2, 4) . Furthermore, the direction of association was similar for antenatal and postnatal glucocorticoid treatment in carriers of the 363S variant. Although this is not a replication in an independent sample, it does decrease the probability that our results were based merely on chance alone.
The clustering of postnatal growth failure and metabolic risk factors in individuals born prematurely (1, 2) resembles the effects of increased glucocorticoid bioactivity. We speculate that there are three explanations with a central role for the hypothalamus-pituitary-adrenal axis possible for these associations. First, it has been convincingly shown that antenatal glucocorticoid treatment to mothers with impending preterm delivery improves neonatal survival, which is attributed to a lower incidence of the respiratory distress syndrome and complications arising from hemodynamic instability (18) . It might be possible that subjects who are genetically more sensitive to the effects of endogenous or exogenous glucocorticoids may survive preterm birth more easily but are predisposed later to metabolic diseases. Second, an extreme stressful insult in early life, such as preterm birth, may induce alterations in the epigenetic code. Experiments in rats have shown that pups with low-grooming mothers have hypermethylation at the GR gene promoter in the hippocampus, leading to less GR expression in central feedback regions and, hence, enhanced stress responsiveness (20) . Third, the current findings suggest that antenatal glucocorticoid treatment has GR genotype-dependent effects on the later metabolic profile.
In conclusion, in prematurely born individuals carrying the 363S variant, antenatal glucocorticoid therapy predisposes to abdominal adiposity at age 19 yr. Replication of our findings in larger preterm cohorts is required. 
